Abstract: A wearable wound simulant for simulating a battlefield wound is presented. The simulant facilitates a graphically and functionally realistic medical training tool. The simulant includes a skin replica and a wound. The skin replica is shaped to conformably contact and cover a body region either in part or whole. The skin replica further includes a plurality of bendable layers arranged to approximately replicate the visual and tactile properties of human tissue and at least one tear resistant layer composed of a fabric material disposed between two bendable layers. At least one tear resistant layer is less stretchable than the elastic limit of the bendable layers so as to prevent failure thereof. The bendable and tear resistant layers form a self-sealing structure. A three-dimensional wound structure is disposed along the skin replica so as to replicate the appearance and functionality of a penetrating or non-penetrating injury.

Abstract: A wearable wound simulant including a skin replica having the appearance of a particular region of the human body, examples including but not limited to a leg, arm, torso, or stomach, and a wound disposed along the skin replica is described. The skin replica includes a plurality of bendable layers arranged to replicate the visual and tactile properties of human tissues and at least one tear resistant layer comprised of a fabric material disposed between two bendable layers. The tear resistant layers are less stretchable than the bendable layers so as to prevent the bendable layers from stretching beyond their failure threshold. Design elements of the present invention facilitate the visual, tactile, and functional aspects of a battlefield wound so as to allow for the diagnosis of injuries associated therewith.

Abstract: The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

Abstract: An electroluminescent (EL) one-way vision, see-through graphics panel comprises a sheet of light permeable material with a uniform electrically conductive coating. A print pattern comprising an electroluminescent ink system partially covers the sheet of light permeable material forms an ‘EL lamp’. A design is superimposed on, or forms part of, the print pattern such that the design is visible from only one side of the panel. The design can be a uniform color, but is typically a multi-color graphic image. The EL lamp illuminates the design when subjected to an electrical current. If the light permeable material is transparent, through vision is possible from the other side of the panel through the unprinted portions of the transparent material. A dark colored opaque mask layer faces in the direction of the other side of the panel to mask the other print pattern layers and enable good through vision.

Abstract: Techniques for determining one or more heat transfer characteristic values of a structure, such as an electronic device, are disclosed. A heat flux vector magnitude and a temperature gradient vector magnitude for a portion of the structure are determined, and a product of the heat flux vector magnitude with the temperature gradient vector magnitude is obtained. More particularly, the dot product of the heat flux vector magnitude with the temperature gradient vector magnitude may be obtained to provide a bottleneck heat transfer characteristic value. Alternately or additionally, a cross product (or related operation) of the heat flux vector magnitude with the temperature gradient vector magnitude is obtained to produce a shortcut heat transfer characteristic value.

Abstract: In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.

Abstract: A magazine well plug used to render a weapon safe and/or to prevent sand, water, and other contaminants from entering a weapon is described. The magazine well plug includes a main body substantially shaped to conform to the interior of a magazine well, an optional flange substantially disposed about the main body, and an optional grip element disposed at one end of the main body facilitating insertion and removal of the plug with respect to the magazine well. The main body and flange are comprised of one or more compressible materials. The main body is dimensionally larger than one or more dimensions within a magazine well so as to require the main body to be compressed in part or whole when inserted into a magazine well. The invention avoids openings inherent with rigid plugs, thereby preventing solid and/or liquid contaminants from entering a magazine well.

Abstract: A magazine well plug used to render a weapon safe and/or to prevent sand, water, and other contaminants from entering a weapon is described. The magazine well plug includes a main body substantially shaped to conform to the interior of a magazine well, an optional flange substantially disposed about the main body, and an optional grip element disposed at one end of the main body facilitating insertion and removal of the plug with respect to the magazine well. The main body and flange are comprised of on e or more compressible materials. The main body is dimensionally larger than one or more dimensions within a magazine well so as to require the main body to be compressed in part or whole when inserted into a magazine well. The invention avoids openings inherent with rigid plugs, thereby preventing solid and/or liquid contaminants from entering a magazine well.

Abstract: This application discloses a novel formulation containing a 3-amino-4-substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation.

Abstract: The present invention provides compositions and methods of treating proliferative disorders using combination therapy with a first agent that specifically inhibits DNA polymerase alpha and a second agent that inhibits protein kinases, such as Chk1.

Abstract: The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

Abstract: A wearable wound simulant including a skin replica having the appearance of a particular region of the human body, examples including but not limited to a leg, arm, torso, or stomach, and a wound disposed along the skin replica is described. The skin replica includes a plurality of bendable layers arranged to replicate the visual and tactile properties of human tissues and at least one tear resistant layer comprised of a fabric material disposed between two bendable layers. The tear resistant layers are less stretchable than the bendable layers so as to prevent the bendable layers from stretching beyond their failure threshold. Design elements of the present invention facilitate the visual, tactile, and functional aspects of a battlefield wound so as to allow for the diagnosis of injuries associated therewith.

Abstract: A novel process for preparing a compound of formula (I) which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof, without isolating any intermediates.

Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: An electroluminescent (EL) one-way vision, see-through graphics panel comprises a sheet of light permeable material with a uniform electrically conductive coating. A print pattern comprising an electroluminescent ink system partially covers the sheet of light permeable material forms an ‘EL lamp’. A design is superimposed on, or forms part of, the print pattern such that the design is visible from only one side of the panel. The design can be a uniform colour, but is typically a multi-colour graphic image. The EL lamp illuminates the design when subjected to an electrical current. If the light permeable material is transparent, through vision is possible from the other side of the panel through the imprinted portions of the transparent material. A dark coloured opaque mask layer faces in the direction of the other side of the panel to mask the other print pattern layers and enable good through vision.

Abstract: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: In order to allow a smoke detector unit to be utilized in, for example, a domestic kitchen environment, appliances whose operation is commonly associated with the generation of non-hazardous smoke or aerosols are connected to a conventional mains supply socket via a current monitoring unit. The current monitoring units include a radio transceiver, which transmits the operational status of the appliances to a corresponding transceiver of the smoke detector unit 1. If the signals transmitted by the current monitoring units indicate that the appliances and are off, the smoke detector unit generates a warning signal when the smoke density exceeds a lower threshold. If one of the appliances and is detected to be on, the smoke detector unit generates a warning signal only when a second, higher threshold of smoke density is exceeded. Optionally, when the higher smoke density threshold is exceeded; the smoke detector unit transmits the signal to the current monitoring unit to power off the appliances.

Abstract: A fuel cell system includes a de-sulfurization tank, a reformer, a pressure monitoring device and a fuel cell stack. The de-sulfurization tank includes an agent that is adapted to remove sulfur compounds and is capable of undergoing a conditioning cycle. The tank includes an inlet to receive a first hydrocarbon flow and an outlet to provide a second hydrocarbon flow. The reformer is adapted to convert the second hydrocarbon flow into a reformate flow, which is received by the fuel cell stack. The pressure monitoring device monitors a pressure of the second hydrocarbon flow, a circuit of the fuel cell system is coupled to the pressure monitoring device to determine whether the conditioning of the tank is complete based on the pressure.

Abstract: The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.